CTLA-4 Blockade in Therapy of Prostate Cancer: Therapeutic Mechanisms and New Directions

About CTLA-4 Blockade in Therapy of Prostate Cancer: Therapeutic Mechanisms and New Directions

Immunotherapy is a treatment for cancer that involves directing a patient’s immune response against their cancer to cause elimination of the tumor. A variety of immunotherapeutic strategies for the treatment of prostate cancer are under development. There is a significant need for discovery of blood markers that will herald an anti-tumor response as well as warn of an impending adverse event due to the therapy. Drs. Sharma and Allison are performing clinical evaluation of advanced immunotherapies. They plan to perform a rigorous molecular analysis of the patient response to immunotherapy for treatment of prostate cancer. The goal is to use these findings to develop more effective and safer immunotherapeutic treatments for prostate cancer.
Research team member: Dr. Neal R. Rosen, Memorial Sloan-Kettering Cancer Center.

Lead Investigators:

Dr. James Allison, Memorial Sloan-Kettering Cancer Center and Dr. Padmanee Sharma, M.D. Anderson Cancer Center